<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740246</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT05006</org_study_id>
    <nct_id>NCT00740246</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia</brief_title>
  <official_title>A Multi-Center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerability of VIT-45 in the
      treatment of Iron Deficiency Anemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
  </primary_outcome>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIT-45</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects &gt; or = 18 years of age and able to give informed consent

          -  Historical laboratory Hgb indicative of anemia within 3 months prior to screening
             visit

          -  Screening Visit laboratory Hgb indicative of anemia

          -  Screening Visit ferritin indicative of iron deficiency anemia

        Exclusion Criteria:

          -  Known hypersensitivity to VIT-45

          -  Previously received VIT-45

          -  Parenteral iron in the 4 weeks prior to screening

          -  Chronic or serious active infection

          -  Malignancy history

          -  AST or ALT greater than the upper limit of normal

          -  Anticipated need for surgery or initiation of dialysis during the study

          -  Pregnant or sexually active females who are not willing to use an effective form of
             birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Luitpold Pharmaceuticals</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Seid MH, Valaoras TG, Barish CF, Dinh Q. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Management 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Management 2007.</citation>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>August 21, 2008</last_update_submitted>
  <last_update_submitted_qc>August 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 21, 2013</submitted>
    <returned>December 10, 2013</returned>
    <submitted>July 1, 2015</submitted>
    <returned>July 28, 2015</returned>
    <submitted>July 29, 2015</submitted>
    <returned>August 26, 2015</returned>
    <submitted>May 8, 2017</submitted>
    <returned>December 13, 2017</returned>
    <submitted>April 20, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

